Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating reissued by analysts at Citigroup in a research report issued on Tuesday, January 9th, Marketbeat Ratings reports. They presently have a $388.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $380.00. Citigroup’s price objective indicates a potential upside of 11.54% from the stock’s previous close.
Several other research analysts have also issued reports on REGN. BTIG Research reissued a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. Piper Jaffray Companies reissued an “overweight” rating and issued a $540.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, September 29th. Oppenheimer reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. SunTrust Banks reaffirmed a “hold” rating and set a $435.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 2nd. Finally, BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $468.15.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at $347.86 on Tuesday. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a fifty-two week low of $340.65 and a fifty-two week high of $543.55. The stock has a market cap of $37,370.00, a PE ratio of 31.59, a price-to-earnings-growth ratio of 1.33 and a beta of 1.47.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter last year, the company earned $3.13 earnings per share. The firm’s revenue was up 23.0% on a year-over-year basis. equities research analysts predict that Regeneron Pharmaceuticals will post 13.55 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Fieldpoint Private Securities LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $130,000. FNY Partners Fund LP increased its stake in shares of Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of Regeneron Pharmaceuticals by 495.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 307 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $206,000. Finally, Vident Investment Advisory LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $200,000. Hedge funds and other institutional investors own 66.82% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/04/regeneron-pharmaceuticals-regn-neutral-rating-reiterated-at-citigroup.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.